Routine board transition with no immediate financial or operational catalysts. Monitor upcoming quarterly filings for any change in strategic direction; Dr. Reid's biomanufacturing background may support FSI's expansion into food/nutrition markets but no concrete plans announced.
Price Chart
Executive Summary
FSI filed an 8-K announcing the resignation of director John Bientjes after nearly 30 years of service, the appointment of Dr. Kim Reid as a director and audit committee member, and the appointment of Davis Fynn as audit committee chair. This is a routine board refresh: the outgoing director's exit was not due to any disagreement, and the incoming director, Dr. Reid, brings a PhD in Biology and deep expertise in biomanufacturing and mRNA-LNP production, potentially signaling strategic interest in expanding FSI's food/nutrition and biopolymer capabilities.
Key Facts
- John Bientjes resigned as director and audit committee chair after nearly 30 years of service, not due to any disagreement.
- Dr. Kim Reid appointed as director and audit committee member, serving until next annual meeting.
- Dr. Reid holds a PhD in Biology, has expertise in mRNA-LNP biomanufacturing, and was a fighter pilot in the Royal Canadian Air Force.
- Davis Fynn, a long-serving audit committee member, appointed as audit committee chair.
Financial Impact
No financial data or material monetary figure disclosed in the filing.
Risk Factors
- No material risks identified; the board refresh is routine and non-disruptive.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-040991 |
| Exhibit: ex99-1.htm | 0001493152-26-040991 |
| Document: 0001493152-26-040991-index-headers.html | 0001493152-26-040991 |
| Document: 0001493152-26-040991-index.html | 0001493152-26-040991 |
| Document: 0001493152-26-040991.txt | 0001493152-26-040991 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $6.31 $6.36 | ▲ +0.76% | ▲ +0.91% | $6.26 (−0.79%) |
Oct 6, 2026 20d ago | DEF 14A | $6.28 $6.01 | ▼ −4.30% | ▼ −3.32% | $6.26 (−0.32%) |
Sep 1, 2026 7w ago | 8-K | $5.78 $5.70 | ▼ −1.38% | ▼ −1.47% | $6.26 (+8.30%) |
Aug 18, 2026 9w ago | 8-K | $5.25 $5.50 | ▼ −4.76% | ▼ −4.96% | $6.26 (−19.24%) |
Aug 14, 2026 10w ago | Press Release | $5.39 $5.30 | ▲ +1.67% | ▲ +0.48% | $6.26 (−16.14%) |
Jul 20, 2026 14w ago | Press Release | $5.22 $5.00 | ▲ +4.21% | ▲ +2.99% | $6.26 (−19.92%) |
Jul 1, 2026 16w ago | 8-K | $6.56 $5.96 | ▲ +9.15% | ▲ +9.41% | $6.26 (+4.57%) |
Jul 1, 2026 16w ago | 424B5 | $6.56 $5.96 | ▲ +9.15% | ▲ +9.41% | $6.26 (+4.57%) |
Jun 8, 2026 20w ago | 8-K | $6.40 $6.37 | ▼ −0.47% | ▼ −2.58% | $6.26 (−2.19%) |
May 18, 2026 23w ago | 8-K | $6.10 $6.44 | ▲ +5.57% | ▲ +3.96% | $6.26 (+2.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers